APA (7th ed.) Citation

H, H., BC, C., YJ, K., SH, L., P, D., A, A., . . . S, L. (2026). Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. Lung cancer (Amsterdam, Netherlands), 214, 109305. https://doi.org/10.1016/j.lungcan.2026.109305

Chicago Style (17th ed.) Citation

H, Hayashi, et al. "Overall Survival for Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in Asian Participants with EGFR-mutant Advanced NSCLC: A MARIPOSA Subset Analysis." Lung Cancer (Amsterdam, Netherlands) 214 (2026): 109305. https://doi.org/10.1016/j.lungcan.2026.109305.

MLA (9th ed.) Citation

H, Hayashi, et al. "Overall Survival for Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in Asian Participants with EGFR-mutant Advanced NSCLC: A MARIPOSA Subset Analysis." Lung Cancer (Amsterdam, Netherlands), vol. 214, 2026, p. 109305, https://doi.org/10.1016/j.lungcan.2026.109305.